Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for older adults with rare blood disorder: safer transplant regimen under study

NCT ID NCT07586735

Recruiting now Disease control Sponsor: Peking University People's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 07, 2026 · Updated 3 times

Summary

This study tests a new combination of drugs (busulfan, fludarabine, cyclophosphamide, and r-ATG) as preparation for a stem cell transplant in people aged 40-60 with severe aplastic anemia. The goal is to see if this regimen helps the transplant succeed with fewer failures. The study will follow 64 participants across multiple centers to measure survival and recovery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
busulfan, fludarabine, cyclophosphamide, and rabbit anti-thymocyte globulin (r-ATG)
What this could lead to
If successful, this could offer a safer transplant option for older adults with severe aplastic anemia, potentially improving survival and reducing complications.
What could go wrong
This is an early-stage observational study with only 64 participants, so results may not apply to everyone. The drug combination can cause serious side effects like infection or organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for APLASTIC ANAEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired aplastic anemia aplastic anemia idiopathic aplastic anemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

APLASTIC ANAEMIA BUSULFAN 0.8 MG/KG/Q6H (DAYS -8 TO -7) FLUDARABINE 30MG/M2/DAY (DAYS -6 TO -2) CYCLOPHOSPHAMIDE 25 MG/KG/DAY AND R-ATG 2.5 MG/KG/DAY (DAYS -5 TO -2) HEMATOPOIETIC CELL TRANSPLANT SEVERE APLASTIC ANEMIA

Contacts and locations

Locations

  • Peking Universtiy Peoples' Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100044, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.